JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia
| Autor: | Walter Ageno, Leonardo Campiotti, Achille Venco, Francesco Solbiati, Lorena Appio |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Cancer Research
ABL Essential thrombocythemia business.industry Point mutation Hematopoietic growth factor breakpoint cluster region Myeloid leukemia Hematology medicine.disease Polycythemia vera Oncology hemic and lymphatic diseases Immunology Cancer research medicine business neoplasms Tyrosine kinase |
| Popis: | JAK2 is a tyrosine kinase that plays an important role in the signaling pathways of many hematopoietic growth factor receptors. A single acquired point mutation – V617F – in JAK2 occurs in the great majority of patients with polycythemia vera (PV) and approximately half of the patients with idiopathic myelofibrosis (IMF) or essential thrombocythemia (ET). In contrast, the JAK2-V617F mutation is only rarely found in chronic myeloid leukemia (CML) but, recently, some authors have reported the coexistence of JAK2V617F and BCR/ABL+ in CML patients expressing the p210 BCR–ABL oncoprotein. Here, we report a CML patient with the expression of p210/b2a2 type BCR–ABL transcript and JAK2V617F mutation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|